Kiev. Ukraine. Ukraine Gate – February 16, 2021 – Health
Researchers at the QIMR Berghofer Medical Research Institute have developed a test that helps predict the effectiveness of treatment for patients with metastatic melanoma, one of the most aggressive cancers.
The test measures the levels of the LC3B protein in cancer cells. Elevated LC3B levels in patients are associated with high efficacy in melanoma therapy known as immune checkpoint inhibitor immunotherapy.
The study found that the survival rate among patients with high levels of LC3B protein three years after melanoma therapy was 95% compared with 60% of patients with low levels of LC3B.
The study also found that patients with metastatic melanoma have very high levels of the epigenetic enzyme G9a, which acts on the LC3B protein.
Read also: Increasing in the Number of COVID-19 Patients in Ukraine!
Scientists have found that inhibition of the G9a enzyme leads to higher levels of LC3B proteins, activating the body’s immune system to fight melanoma.